MOORESTOWN, N.J., Oct. 04, 2016 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the closing of its initial public offering of 4,945,000 shares of common stock at an initial public offering price of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 645,000 additional shares of common stock. All of the shares in the offering were offered by Tabula Rasa. Tabula Rasa’s common stock is listed on the NASDAQ Global Market under the ticker symbol "TRHC." Tabula Rasa estimates net proceeds from the offering to be approximately $51.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Wells Fargo Securities and UBS Investment Bank acted as joint-book running managers for the offering. Piper Jaffray also acted as a book-runner and Baird and Stifel acted as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 28, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to this offering, when available, may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov, or alternatively, from: Wells Fargo Securities, LLC by mailing: Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by email: [email protected] or by Telephone: (800) 326-5897, or from UBS Securities LLC by mailing: Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by Telephone: (888) 827-7275.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.tabularasahealthcare.com.
Contact Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 



